Survival from common and rare cancers in Germany in the early 21st century

Abstract

German cancer survival estimates are mostly higher than the 2000-2002 pan-European estimates. Further research is needed to investigate causes responsible for differences between German and USA cancer survival rates.

Determinants and interpretation of death certificate only proportions in the initial years of newly established cancer registries

“…Such an approach has been taken, for example, in a recent collaborative study on cancer survival in Germany, where new cancer registries have been established in recent years, and a decision had to be made which cancer registries to include in the joint analysis. 31,32 In the longer run, DCO proportions reflect underreporting to a greater extent, even though they are affected by multiple other factors, in particular cancer prognosis. For some cancers with relatively high proportions of late deaths, such as breast cancer or prostate cancer, several percent units of DCO proportions might still be explained by cases diagnosed prior to registration even as late as in the 10th year of registration.…”

Deriving Valid Population–Based Cancer Survival Estimates in the Presence of Nonnegligible Proportions of Cancers Notified by Death Certificates Only

“…Data from the population-based Saarland Cancer Registry were used, which is operating since 1968 and covers the federal state of Saarland in southwestern Germany with about 1.03 million inhabitants. The registry regularly contributes to descriptive and analytic studies in national or international collaborations (1)(2)(3)(12)(13)(14).…”

EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits

“…We learned that coverage seemed optimal in 20 of the 27 smaller European countries (610 million people -15 of the 19 member states of the European Union); yet this was rather suboptimal in the southeast as shown in an overview study of trends in incidence and mortality of 17 frequent cancers [6]. In the bigger member states (MSs) (P15 million) coverage varied from 15% to 25% in Poland, Romania, France [7] and Spain [8] to about 50% in Italy [9] and Germany [10] and 100% in the Netherlands and the United Kingdom (UK). Studying best CR practices showed a higher and broader intensity of use of CR data to be based on verifiable input and good linkages as well as on a research department with broad external contacts with the various stakeholders in oncology and public health, active in about five clinical oncology and public health research domains (www.eurocourse.org -deliverables -D1.1) [11].…”